These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

879 related items for PubMed ID: 26191276

  • 1. Prognostic and predictive values of Nrf2, Keap1, p16 and E-cadherin expression in ovarian epithelial carcinoma.
    Liew PL, Hsu CS, Liu WM, Lee YC, Lee YC, Chen CL.
    Int J Clin Exp Pathol; 2015; 8(5):5642-9. PubMed ID: 26191276
    [Abstract] [Full Text] [Related]

  • 2. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
    Lee YH, Heo JH, Kim TH, Kang H, Kim G, Kim J, Cho SH, An HJ.
    Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
    [Abstract] [Full Text] [Related]

  • 3. DEF6 expression in ovarian carcinoma correlates with poor patient survival.
    Liew PL, Fang CY, Lee YC, Lee YC, Chen CL, Chu JS.
    Diagn Pathol; 2016 Aug 03; 11(1):68. PubMed ID: 27488395
    [Abstract] [Full Text] [Related]

  • 4. Expression Patterns of Nrf2 and Keap1 in Ovarian Cancer Cells and their Prognostic Role in Disease Recurrence and Patient Survival.
    Cho HY, Kim K, Kim YB, Kim H, No JH.
    Int J Gynecol Cancer; 2017 Mar 03; 27(3):412-419. PubMed ID: 28129239
    [Abstract] [Full Text] [Related]

  • 5. Prognostic role of E-cadherin in patients with advanced serous ovarian cancer.
    Bačić B, Haller H, Mrklić I, Košta V, Čarić A, Tomić S.
    Arch Gynecol Obstet; 2013 Jun 03; 287(6):1219-24. PubMed ID: 23269354
    [Abstract] [Full Text] [Related]

  • 6. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.
    Skírnisdóttir I, Seidal T.
    Int J Gynecol Cancer; 2011 Aug 03; 21(6):1024-31. PubMed ID: 21792012
    [Abstract] [Full Text] [Related]

  • 7. Wnt/β-catenin pathway as a potential prognostic and predictive marker in patients with advanced ovarian cancer.
    Bodnar L, Stanczak A, Cierniak S, Smoter M, Cichowicz M, Kozlowski W, Szczylik C, Wieczorek M, Lamparska-Przybysz M.
    J Ovarian Res; 2014 Feb 06; 7():16. PubMed ID: 24499657
    [Abstract] [Full Text] [Related]

  • 8. Clear cell carcinomas of the ovary: a mono-institutional study of 73 cases in China with an analysis of the prognostic significance of clinicopathological parameters and IMP3 expression.
    Bi R, Shen X, Zhang W, Cheng Y, Feng Z, Cai X, Yang W.
    Diagn Pathol; 2016 Feb 02; 11():17. PubMed ID: 26837693
    [Abstract] [Full Text] [Related]

  • 9. Nuclear β-catenin positivity as a predictive marker of long-term survival in advanced epithelial ovarian cancer.
    Nagy B, Tóth L, Molnár P, Méhes G, Thurzó L, Póka R, Hernádi Z.
    Pathol Res Pract; 2017 Aug 02; 213(8):915-921. PubMed ID: 28651933
    [Abstract] [Full Text] [Related]

  • 10. Association of p21, p21 p27 and p21 p53 status to histological subtypes and prognosis in low-stage epithelial ovarian cancer.
    Skirnisdottir I, Seidal T.
    Cancer Genomics Proteomics; 2013 Aug 02; 10(1):27-34. PubMed ID: 23382584
    [Abstract] [Full Text] [Related]

  • 11. The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions.
    Davidson B, Holth A, Hellesylt E, Tan TZ, Huang RY, Tropé C, Nesland JM, Thiery JP.
    Hum Pathol; 2015 Jan 02; 46(1):1-8. PubMed ID: 25455994
    [Abstract] [Full Text] [Related]

  • 12. Nuclear factor erythroid 2-related factors 1 and 2 are able to define the worst prognosis group among high-risk diffuse large B cell lymphomas treated with R-CHOEP.
    Kari E, Teppo HR, Haapasaari KM, Kuusisto MEL, Lemma A, Karihtala P, Pirinen R, Soini Y, Jantunen E, Turpeenniemi-Hujanen T, Kuittinen O.
    J Clin Pathol; 2019 Apr 02; 72(4):316-321. PubMed ID: 30755497
    [Abstract] [Full Text] [Related]

  • 13. Prognostic value of tissue protein expression levels of MIB-1 (Ki-67) in Danish ovarian cancer patients. From the 'MALOVA' ovarian cancer study.
    Heeran MC, Høgdall CK, Kjaer SK, Christensen L, Jensen A, Blaakaer J, Christensen IJ, Høgdall EV.
    APMIS; 2013 Dec 02; 121(12):1177-86. PubMed ID: 23594232
    [Abstract] [Full Text] [Related]

  • 14. Phospho-histone H2AX is a diagnostic and prognostic marker for epithelial ovarian cancer.
    Mei L, Hu Q, Peng J, Ruan J, Zou J, Huang Q, Liu S, Wang H.
    Int J Clin Exp Pathol; 2015 Dec 02; 8(5):5597-602. PubMed ID: 26191270
    [Abstract] [Full Text] [Related]

  • 15. Prognostic significance of E-cadherin-catenin complex in epithelial ovarian cancer.
    Voutilainen KA, Anttila MA, Sillanpää SM, Ropponen KM, Saarikoski SV, Juhola MT, Kosma VM.
    J Clin Pathol; 2006 May 02; 59(5):460-7. PubMed ID: 16461565
    [Abstract] [Full Text] [Related]

  • 16. Morphological and Immunohistochemical Reevaluation of Tumors Initially Diagnosed as Ovarian Endometrioid Carcinoma With Emphasis on High-grade Tumors.
    Lim D, Murali R, Murray MP, Veras E, Park KJ, Soslow RA.
    Am J Surg Pathol; 2016 Mar 02; 40(3):302-12. PubMed ID: 26551621
    [Abstract] [Full Text] [Related]

  • 17. Keap1 expression has independent prognostic value in pancreatic adenocarcinomas.
    Isohookana J, Haapasaari KM, Soini Y, Karihtala P.
    Diagn Pathol; 2015 Apr 16; 10():28. PubMed ID: 25879528
    [Abstract] [Full Text] [Related]

  • 18. Clinical significance of E-cadherin, β-catenin, vimentin and S100A4 expression in completely resected squamous cell lung carcinoma.
    Zhang H, Liu J, Yue D, Gao L, Wang D, Zhang H, Wang C.
    J Clin Pathol; 2013 Nov 16; 66(11):937-45. PubMed ID: 23853314
    [Abstract] [Full Text] [Related]

  • 19. Increased BTB-Kelch type substrate adaptor protein immunoreactivity associates with advanced stage and poor differentiation in renal cell carcinoma.
    Ronkainen H, Vaarala MH, Kauppila S, Soini Y, Paavonen TK, Rask J, Hirvikoski P.
    Oncol Rep; 2009 Jun 16; 21(6):1519-23. PubMed ID: 19424632
    [Abstract] [Full Text] [Related]

  • 20. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA, Todeschini P, Siegel ER, Calza S, Cappella P, Ardighieri L, Cadei M, Bugatti M, Romani C, Bandiera E, Zanotti L, Tassone L, Guarino D, Santonocito C, Capoluongo ED, Beltrame L, Erba E, Marchini S, D'Incalci M, Donzelli C, Santin AD, Pecorelli S, Sartori E, Bignotti E, Odicino F, Ravaggi A.
    J Exp Clin Cancer Res; 2017 May 08; 36(1):63. PubMed ID: 28482906
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.